PMS-CLONAZEPAM 0.25 MG
CLONAZEPAM : 0.25 MG · DIN 02179660 · PHARMASCIENCE INC
Health Canada status: MARKETED
What is PMS-CLONAZEPAM?
PMS-CLONAZEPAM 0.25 MG contains CLONAZEPAM : 0.25 MG. It is listed in the Health Canada Drug Product Database under DIN 02179660, held by PHARMASCIENCE INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 31-Dec-1995. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is PMS-CLONAZEPAM used for?
Alone or as adjunct for myoclonic and akinetic seizures, Lennox-Gastaut syndrome, and absence spells (petit mal) refractory to succinimides.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02179660 |
|---|---|
| Brand name | PMS-CLONAZEPAM |
| Generic / active ingredient | CLONAZEPAM : 0.25 MG |
| Manufacturer | PHARMASCIENCE INC |
| Strength | 0.25 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | TARGETED SUBSTANCES (CDSA IV) |
| ATC code | N03AE01 CLONAZEPAM |
| AHFS class | 28:12.08 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 31-Dec-1995 |
| Original market date | 1995-12-31 00:00:00 |
How is it administered?
Adults: Initial max 1.5 mg/day in 3 doses; maintenance 8-10 mg/day. Pediatrics: 0.01-0.03 mg/kg/day initially. Taper gradually to discontinue. Swallow whole with water.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text snippet (standard practice is 15-30°C, but section 11 is not fully visible).
How is it supplied?
HDPE bottles of 100, 500, and 1000 tablets (varies by strength).
Contraindications
Hypersensitivity to benzodiazepines; severe respiratory insufficiency; severe hepatic impairment; sleep apnea syndrome; myasthenia gravis; narrow angle glaucoma.
Warnings and precautions
Risk of addiction, abuse, and misuse; life-threatening withdrawal symptoms; profound sedation/respiratory depression if used with opioids; risk of falls and fractures.
What can be used instead?
Other Canadian products sharing ATC code N03AE01 CLONAZEPAM. 8 of 55 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-CLONAZEPAM | 0.5 MG | TABLET | APOTEX INC | MARKETED | DIN 02177889 |
| APO-CLONAZEPAM | 2 MG | TABLET | APOTEX INC | MARKETED | DIN 02177897 |
| PMS-CLONAZEPAM | 1 MG | TABLET | PHARMASCIENCE INC | MARKETED | DIN 02048728 |
| PMS-CLONAZEPAM | 2 MG | TABLET | PHARMASCIENCE INC | MARKETED | DIN 02048736 |
| PMS-CLONAZEPAM-R | 0.5 MG | TABLET | PHARMASCIENCE INC | MARKETED | DIN 02207818 |
| RIVOTRIL | 0.5 MG | TABLET | CHEPLAPHARM ARZNEIMITTEL GMBH | MARKETED | DIN 00382825 |
| RIVOTRIL | 2 MG | TABLET | CHEPLAPHARM ARZNEIMITTEL GMBH | MARKETED | DIN 00382841 |
| ACCEL-CLONAZEPAM | 0.5 MG | TABLET | ACCEL PHARMA INC | CANCELLED PRE MARKET | DIN 02365243 |
| ACCEL-CLONAZEPAM | 1.0 MG | TABLET | ACCEL PHARMA INC | CANCELLED PRE MARKET | DIN 02365251 |
| ACCEL-CLONAZEPAM | 2.0 MG | TABLET | ACCEL PHARMA INC | CANCELLED PRE MARKET | DIN 02365278 |
Who else supplies CLONAZEPAM worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. CLONAZEPAM appears in 1436 registered pack listings across 11 markets, published on 9 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.